AACR 2014: Current Concepts in Organ Site Research: Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise

Tuesday, April 08, 2014, 10:30 AM -12:30 PM
Room 11, San Diego Convention Center

Multiple genome-wide analyses of genetic events in invasive bladder cancer have recently been reported, highlighting both kinase-activating mutations and other mechanisms of activation in FGFR3, ERBB2, and ERBB3; and activating and inactivating mutations in the PI3K-mTOR pathway (PIK3CA, PTEN, TSC1). Furthermore, multiple cell cycle and chromatin regulatory gene mutations are seen in the majority of invasive bladder cancer. In addition, metabolic changes in metastatic bladder cancer have been identified which are similar to those seen in glycogen storage disease. These findings introduce a new era in bladder cancer research in which therapies targeting these alterations should be tested in genotype-restricted patient populations. In this session, these recent findings will be reviewed in detail with an eye toward therapeutic strategies.


  • Chairperson
    • David J. Kwiatkowski. Brigham & Women's Hospital, Boston, Mass.
  • Genomic insights from the TCGA analysis, and therapeutic targets in invasive bladder cancer
    • David J. Kwiatkowski. Brigham & Women's Hospital, Boston, Mass.
  • Discussion
  • Therapeutic implications of FGF receptor activation in bladder cancer
    • Margaret Knowles. Cancer Research U.K., Leeds, United Kingdom
  • Discussion
  • Disrupted glycogen metabolism regulators: An unexpected common denominator between human glycogen storage diseases and advanced bladder cancer
    • Dan Theodorescu. Univ. of Colorado Cancer Ctr., Aurora, Colo.
  • Discussion
  • Next Generation clinical trials for translating the genomic landscape in bladder cancer
    • Seth P. Lerner. Baylor College of Medicine, Houston, Texas
  • Discussion
  • Panel Discussion

For more information, please visit the AACR website.